Syntrix to present at 2025 Life Science Innovation Northwest (LSINW)
-AUBURN, WASHINGTON — Syntrix Pharmaceuticals is pleased to announce that it has been invited to present development and financing goals…
ASCO 2024 selects SX-682 for oral podium presentation of positive first-in-class efficacy results in patients with metastatic melanoma
-– Safety and efficacy data will be presented for first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab in patients with…
New study finds SX-682 leads to “unprecedented” response and cures in pancreatic cancer models
-AUBURN, WASHINGTON —A new study led by researchers at MD Anderson Cancer Center revealed for the first time that SX-682…
First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
-— Phase 1 Findings Presented in Oral Session at 2022 American Society of Hematology (ASH) Meeting Support CXCR1/2 as Promising…
New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer
-A new study led by researchers at NYU Grossman School of Medicine and its Laura and Isaac Perlmutter Cancer Center…
Two New Reports Show SX-682 Blocks Key Immunosuppressive Tumor Cells to Enhance Checkpoint Inhibitors and NK-Based Cell Immunotherapies
-Researchers at the Fred Hutchinson Cancer Research Center and the National Institutes of Health (NIH) independently showed SX-682 eradicates pivotal…
Syntrix Pharmaceuticals to Present Positive Desmetramadol Trial Results at the 2019 Pain Management SUMMIT
-Desmetramadol trial featured on the October cover of The Journal of Pain AUBURN, WASHINGTON — Syntrix Pharmaceuticals, Inc., a leading…
Syntrix Announces Dosing of First Patient in Phase 1/2 Clinical Trial of SX-682 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Melanoma
-– Initial Clinical Data Expected in First Half of 2020 – AUBURN, WASHINGTON — Syntrix Pharmaceuticals today announced that it…
Syntrix Reports Positive Clinical Trials Showing Desmetramadol Has the Analgesic and Side Effect Profile of Tramadol Without Its Metabolic Liabilities
-Study successfully met its endpoints and provides basis for pivotal Phase 3 trial AUBURN, WASHINGTON — Syntrix Pharmaceuticals today announced…
Researchers Report SX-682 Could Enhance Multiple Forms of T Cell-Based Immunotherapies in Solid Tumors
-Researchers at the National Institutes of Health (NIH) have shown that inhibition of myeloid-derived suppressor cell (MDSC) trafficking into mouse…
New Study Points to SX-682 as Strategy to Boost Immunotherapy Effectiveness in Advanced Colorectal Cancer
-AUBURN, WASHINGTON — In collaboration with Syntrix Pharmaceuticals, researchers at the University of Texas MD Anderson Cancer Center revealed that…
Syntrix Announces First Patient Cohort Dosed in Phase 2 Study of Desmetramadol in Diabetic Neuropathic Pain
-AUBURN, WASHINGTON — Syntrix Pharmaceuticals today announced the initiation of a Phase 2 study evaluating the efficacy and safety of…
Syntrix Wins $3.4M NIH Grant to Conduct Phase 1/2 trial of SX-682 in Myelodysplastic Syndrome
-AUBURN, WASHINGTON — Syntrix Pharmaceuticals announced this week that it has been awarded a three-year grant worth $3.4 million from…
Desmetramadol featured today in new article by Research Outreach
-Desmetramadol featured today in new article by Research Outreach entitled, “Moving beyond dangerous opioids for pain: Syntrix creates new drug…
Syntrix Wins U.S. Patent 10,046,002 – Method for Treating Cancer Using Chemokine Antagonists
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
World Health Organization’s INN Approves “Desmetramadol” as Generic Name for Omnitram
-Syntrix today announced that the World Health Organization’s International Nonproprietary Name (INN) group have accepted the proposed generic name “Desmetramadol”…
Syntrix Joins National Cancer Institute (NCI) Formulary to Help Expedite Cancer Clinical Trials – Collaboration Will Support Vice President Biden’s Cancer Moonshot Program
-Syntrix today announced their participation in the NCI Formulary, a public-private partnership between the National Cancer Institute (NCI), part of…
Syntrix Doses First Subject with Omnitram to Confirm Pain Relief in Patients for Whom Tramadol is Ineffective
-Large patient populations treated with dangerous Schedule II opioids are expected to benefit from Omnitram, a safer alternative without metabolic…
Syntrix Wins Three U.S. Patents for Omnitram – 9,717,700; 9,717,701; 9,808,432
-Congratulations to Syntrix scientists on their latest issued patents at the United States Patent and Trademark Office. ‘701 Abstract: Disclosed…
Syntrix Wins U.S. Patent 9,707,248 – Use of Thiopyrimidinecarboxamide for Treating Cancer
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
